Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.23%
SPX
-1.60%
IXIC
-2.24%
FTSE
-0.70%
N225
-0.66%
AXJO
-0.92%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...
Join our newsletter to keep up to date with us!

Key Stats

Market Cap
3.67B
Dividend Yield
0.00%
P/E Ratio
-21.40
EPS
-1.00
Revenue
-
Avg. Volume
3.62M

Recently from Cashu

publisher logo
Cashu

Viking Therapeutics Faces Investor Doubts Amid Uncertain Biotech Market Dynamics

5 days ago
publisher logo
Cashu

Viking Therapeutics Advances Innovative Treatments for Metabolic Diseases with VK2809

6 days ago
publisher logo
Cashu

Viking Therapeutics Faces Financial Challenges While Pursuing Drug Development Progress

7 days ago

About

What does VKTX do?
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Sector
💻 Health Care
IPO
CEO
Employees
36 employees
Headquarters
California, USA
Website
http://www.vikingtherapeutics.com
Stocks
Health Care
vktx
Viking Therapeutics
NASDAQ: VKTX
+0.09 (+0.28%)
32.66
USD
At close at Aug 01, 20:39 UTC
Summary
News
Signals
Benchmarks
Financials